This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
DexCom (DXCM) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.
DexCom (DXCM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will DexCom (DXCM) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
DexCom (DXCM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
DexCom (DXCM) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed the most recent trading day at $394.01, moving -1.73% from the previous trading session.
DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, DexCom (DXCM) closed at $387.50, marking a -1.6% move from the previous day.
DexCom (DXCM) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, DexCom (DXCM) closed at $413.84, marking a +0.39% move from the previous day.
4 Best Diabetes Device Stocks to Focus on Amid Coronavirus Crisis
by Debanjana Dey
Here are a few diabetes-centric MedTech stocks that investors can focus on to reap profits amid the pandemic-battered stock market situation.
DexCom (DXCM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, DexCom (DXCM) closed at $389.31, marking a +0.8% move from the previous day.
DexCom Introduces Registry to Monitor Outcomes of G6 System
by Zacks Equity Research
DexCom (DXCM) sets up registry to track outcomes of patients and healthcare professionals using CGM in hospitals.
DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed the most recent trading day at $383.46, moving -1.68% from the previous trading session.
Should iShares Morningstar MidCap Growth ETF (JKH) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKH
DexCom (DXCM) Down 0.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should iShares Morningstar MidCap Growth ETF (JKH) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKH
10 Best-Performing Stocks in Nasdaq ETF as Index Tops 11,000
by Sweta Killa
The latest broad market rally has pushed the tech-heavy Nasdaq Composite Index to new record highs above the 11,000 milestone.
DexCom (DXCM) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) second-quarter results benefit from solid segmental performance.
DexCom (DXCM) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of 154.84% and 11.11%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Why DexCom (DXCM) Might Surprise This Earnings Season
by Zacks Equity Research
DexCom (DXCM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
DexCom (DXCM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) second-quarter results are likely to reflect rising global awareness of its real-time CGM.
DexCom (DXCM) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed at $420.01 in the latest trading session, marking a -1.44% move from the prior day.
S&P 500 Turns Positive for 2020: 10 Top Stocks in ETF
by Sweta Killa
The S&P 500 index turns positive for 2020. We have highlighted 10 stocks that are leading the way in the ETF.
DexCom (DXCM) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain DexCom (DXCM) Stock For Now
by Zacks Equity Research
DexCom (DXCM) continues to gain traction from strong international presence and robust product portfolio.
Should iShares Morningstar MidCap Growth ETF (JKH) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKH
DexCom (DXCM) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed at $413.22 in the latest trading session, marking a -1.13% move from the prior day.
DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed the most recent trading day at $439.64, moving -0.2% from the previous trading session.